Abstract #1124

ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy

Eva-Maria Ratai^1,2, Zheng Zhang³, James Fink⁴, Mark Muzi⁴, Lucy Hanna³, Erin Greco³, Todd Richards⁴, Akiva Mintz⁵, Lale Kostakoglu⁶, Edward Eikman⁷, Melissa Prah⁸, Benjamin Ellingson⁹, Kathleen Schmainda⁸, Gregory Sorensen^1,2, Daniel Barboriak¹⁰, David Mankoff¹¹, and Elizabeth Gerstner¹²

¹Radiology, Massachusetts General Hospital, Boston, MA, United States, ²A. A. Martinos Center for Biomedical Imaging, Charlestown, MA, United States, ³Brown University, Providence, RI, United States, ⁴University of Washington, Seattle, WA, United States, ⁵Wake Forest University, Winston-Salem, NC, United States, ⁶Mt. Sinai Medical Center, New York, NY, United States, ⁷Moffitt Cancer Center, Tampa, FL, United States, ⁸Medical College of Wisconsin, Milwaukee, WI, United States, ⁹UCLA Medical Center, Los Angeles, CA, United States, ¹⁰Duke University, Durham, NC, United States, ¹¹University of Pennsylvania, Philadelphia, PA, United States, ¹²MGH Cancer Center, Massachusetts General Hospital, Boston, MA, United States

The Phase II multi-center trial ACRIN 6684 conducted by the American College of Radiology Imaging Network was designed to assess tumor hypoxia in newly diagnosed glioblastoma (GBM) using [18F] Fluoromisonidazole (FMISO)-PET and MRI. Data from magnetic resonance spectroscopic imaging (MRSI) were available on 17 participants from four sites. The MRS marker of tumor burden (NAA/Cho) was a significant predictor of one-year survival (OS-1). Furthermore, the MRS marker of tumor hypoxia (Lac/Cr) was a significant predictor of six-month progression-free-survival (PFS-6) using receiver operating characteristic (ROC) analysis.

This abstract and the presentation materials are available to members only; a login is required.

Join Here